6 reports

Drug Overview Stivarga (regorafenib; Bayer/Amgen) is a novel diphenylurea oral multikinase inhibitor of angiogenic (vascular endothelial growth factor receptor [VEGFR], platelet-derived growth factor receptor [PDGFR], and fibroblast growth factor receptor [FGFR]), stromal, and oncogenic (KIT, RET, and B-Raf) kinases. VEGF-directed...

  • Magnetic Resonance Imaging
  • Colorectal Cancer

Drug Overview Binimetinib (Array BioPharma/Pierre Fabre/Ono Pharmaceutical) is an orally available inhibitor of mitogen-activated protein kinase kinase (MEK)1/2, which are components of the RAS/RAF/MEK/ERK pathway. Inhibition of MEK1/2 prevents the activation of MEK1/2-dependent effector proteins and transcription factors,...

  • Monoclonal Antibody
  • Colorectal Cancer
  • Healthcare
  • Proteomics

Drug Overview Napabucasin (Dainippon Sumitomo) is designed to selectively and simultaneously inhibit multiple key pathways associated with tumor growth and development by targeting the STAT3 transcription factor. STAT3 activation contributes to growth stimulation, angiogenesis, and resistance to apoptosis, which are all...

  • Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Gastric Cancer

Drug analysis: Avastin

8770 10000 7800

Drug Overview Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential component of the angiogenesis pathway, critical for blood vessel formation, facilitating tumor growth, invasion, and...

  • Monoclonal Antibody
  • Colorectal Cancer
  • Renal Cancer

Disease Overview Colorectal cancer (CRC) is one of the "big four" tumor types, the third most common cancer to affect both men and women, and the third-leading cause of cancer-related death. The main differentiator between colon cancer and rectal cancer is the location of the primary tumor, but identical etiology and similar...

  • Colorectal Cancer

Colorectal cancer

4385 5000 3900

Pipeline candidates for the colorectal cancer market will pursue novel mechanisms of action to distinguish themselves in an increasingly crowded market. This report addresses the following questions: - How are new therapies differentiating themselves in the increasingly crowded and price-sensitive CRC market? - How...

  • Colorectal Cancer
  • United States
  • Japan
  • European Union
  • Cancer Incidence
  • Colorectal Cancer Screening Coverage